New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
09:08 EDTICPTIntercept announces OCA preclinical study data
Intercept announced results from a preclinical study demonstrating the potential protective effects of obeticholic acid, or OCA, in an experimental model of liver disease. The study was presented orally during the opening session of the International Liver Congress 2014, the 49th Annual Meeting of the European Association for the Study of the Liver. The study has also been selected as the best oral abstract in Basic Science at ILC 2014. In the study, OCA administration was shown to have protective effects on bacterial translocation from the ileum in an experimental rat model of cholestasis. The six animals receiving OCA treatment experienced significant reduction of bacteria in mesenteric lymph nodes and all but one of these remained free from bacterial infection in the abdominal cavity. In contrast, all six animals in the control group developed an abdominal infection. OCA treatment was additionally associated with normalized intestinal permeability, along with reduced inflammation of the lymph nodes and spleen. This study is the first to show OCA treatment limits bacterial translocation from the small intestine. In patients with liver cirrhosis, this manifests as spontaneous bacterial peritonitis.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
09:26 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
08:27 EDTICPTIntercept breakthrough designation a significant positive, says Summer Street
Summer Street views the breakthrough therapy designation from the FDA as a significant positive for Intercept. The firm believes the news supports its thesis that Intercept's OCA is potentially a "game changer" in the treatment of NASH. It keeps a Buy rating on the stock with a $650 price target.
January 29, 2015
19:14 EDTICPTOn The Fly: After Hours Movers
Subscribe for More Information
16:31 EDTICPTIntercept gets breakthrough designation from FDA for steatohepatitis treatment
Intercept Pharmaceuticals announced that its investigational product obeticholic acid, or OCA, has received "breakthrough therapy designation" from the FDA for the treatment of patients with nonalcoholic steatohepatitis, or NASH, with liver fibrosis. This indication constitutes a population of patients with a serious and life-threatening condition reflected by a higher risk of progression to cirrhosis and liver failure. OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis, NASH and primary sclerosing cholangitis.
January 22, 2015
07:17 EDTICPTIntercept price target lowered to $300 from $500 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use